Trial Profile
An exploratory pharmacogenomic study of monotherapy erbitux [cetuximab] in subjects with metastatic colorectal cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Colorectal cancer
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 22 Dec 2005 New trial record.